Skip to main content
Clinical Trials/NCT01378260
NCT01378260
Completed
Not Applicable

Comparative Effectiveness Research Study of Peripheral Arterial Disease (PAD)

University of Washington12 sites in 1 country323 target enrollmentJuly 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Peripheral Arterial Disease
Sponsor
University of Washington
Enrollment
323
Locations
12
Primary Endpoint
The primary outcome is the change in score on the Walking Impairment Questionnaire (WIQ) from the baseline assessment to the 12-month assessment.
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The specific aim of this study is to prospectively compare outcomes (functional, quality of life, risk-adjusted clinical event) of medical management, surgical or endovascular (angioplasty or stent placement) interventions for the treatment of claudication caused by peripheral arterial disease. This study will test two major hypotheses;

Hypothesis 1: At 12-months, surgical interventions are associated with greater improvements in function, claudication symptoms, and health-related quality of life (HRQoL) than endovascular procedures or medical management.

Hypothesis 2: At 12-months, surgical and endovascular interventions are associated with greater improvements in function, claudication symptoms, and HRQoL than medical management.

Registry
clinicaltrials.gov
Start Date
July 2011
End Date
August 2015
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

David Flum

Professor

University of Washington

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of claudication
  • Be undergoing one of three treatments for claudication:
  • Surgical bypass (use of synthetic or endogenous (vein) or composite graft to treat lesions in the superficial femoral, common femoral or popliteal artery)
  • Endovascular therapy (angioplasty and/or stent to treat lesions in the superficial femoral, common femoral or popliteal artery)
  • Medical management (i.e. smoking cessation, walking therapy, long-term monitoring by physician)

Exclusion Criteria

  • those with documented acute ischemia, rest pain or ulceration
  • those with claudication determined to be of aortic or iliac origin
  • those with claudication that is not caused by atherosclerotic disease
  • those without access to a telephone or Internet and are unwilling to participate in surveys by mail at home (assess in patient screen)
  • those who otherwise refuse to participate (assessed in patient screen)
  • those who have a diagnosis of dementia confirmed in their medical record
  • those who are not English speaking
  • children and young adults up to and including age 20-years

Outcomes

Primary Outcomes

The primary outcome is the change in score on the Walking Impairment Questionnaire (WIQ) from the baseline assessment to the 12-month assessment.

Time Frame: 12-Months Post-Index Date

The primary outcome of the study, and the outcome on which the study is powered, is the change in score on the WIQ from the baseline assessment to the 12-month assessment. There are three subscales within the WIQ; summary scores will be calculated separately for each - the walk distance, walk speed, stair climb.

Study Sites (12)

Loading locations...

Similar Trials